Company Profile

TESARO, Inc. is an oncology-focused biopharmaceutical company. The Company operates through the business of developing and commercializing of oncology-focused therapeutics segment. It is developing oncology-related product candidates, including rolapitant, niraparib and the product candidates under its immuno-oncology platform. Rolapitant is a potent and long-acting neurokinin-1 receptor antagonist for the prevention of chemotherapy induced nausea and vomiting. Niraparib is an orally active and potent poly (adenosine diphosphate (ADP)-ribose) polymerase inhibitor. It has various ongoing clinical trials evaluating niraparib for the treatment of ovarian or breast cancers. It has initiated a Phase I, dose escalation study for its first immuno-oncology antibody, TSR-042, which targets Programmed cell death protein 1. It has commenced pre-clinical research for its antibody candidate targeting Lymphocyte-activation gene-3 andTSR-033. It has commenced a Phase I clinical trial of TSR-042.

Employees

Sector

Biotechnology & Medical Research

More about the company

08/01/19	GlaxoSmithKline : to look for early-stage assets - CEO	RE
03/12/18	Relief rally boosts Wall Street on U.S.-China trade truce	RE
03/12/18	U.S.-China trade truce triggers European share surge	RE
03/12/18	GSK slows down UK stocks after China-U.S. trade truce	RE
03/12/18	Merck and : GSK slides after buying cancer firm Tesaro for hefty $5.1 billion	RE
03/12/18	Unilever swallows GSK's Indian Horlicks business for $3.8 billion	RE
27/06/18	AstraZeneca : Merck eye $1 billion boost from cancer drug success	RE
19/10/17	China biotech's 'coming out party' masks long road ahead	RE
17/08/17	AstraZeneca : FDA expands use of AstraZeneca/Merck ovarian cancer drug	RE
14/03/17	AstraZeneca : ovarian cancer drug slows disease markedly in study	RE
08/02/17	Exclusive: Cancer drugmaker Tesaro attracts takeover interest - sources	RE
29/06/16	TESARO : Wall Street rebounds from Brexit with second day of big gains	RE
26/06/14	AbbVie : Cancer drug setback tarnishes AstraZeneca's R&D claims	RE

08/01/19	WEDNESDAY DEADLINE REMINDER: The Schall Law Firm Announces It is Investigating Claims against Tesaro, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm	BU
07/01/19	DEADLINE TOMORROW: The Schall Law Firm Announces it is Investigating Claims Against Tesaro, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm	BU
21/12/18	Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Tesaro, Inc. of Class Action Lawsuit and Upcoming Deadline - TSRO	PR
05/12/18	Monteverde & Associates PC Launches An Investigation of the Board of Directors and Officers of Tesaro, Inc. - TSRO	PR
04/12/18	TESARO, Inc. Gives Notice of Anticipated Make-Whole Adjustment Event to Holders of Its Convertible Senior Notes	GL

19/12/18	GSK va contrôler la santé grand public de Pfizer et se scinder
03/12/18	Dow Jones Industrial Average : Wall Street salue la trêve commerciale USA-Chine
03/12/18	Point marchés-Wall Street salue la trêve commerciale USA-Chine (actualisé)
03/12/18	TESARO : GSK va racheter la biotech Tesaro pour 5,1 milliards de dollars
03/12/18	Dow Jones Industrial Average : Les valeurs à suivre à Wall Street

Director	Title	Age	Since
Mary Lynne Hedley BRD	Director/Board Member	63	25/03/2010
Arnold Lewis Oronsky BRD	Director/Board Member	85	31/05/2011
James Armitage BRD	Director/Board Member	79	08/05/2013

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
TESARO INC	+0.03%	+0.40%	-	-	0
WUXI APPTEC CO., LTD.	+1.23%	-3.08%	+53.96%	+87.98%	55.27B
ARGENX SE	+5.09%	+6.24%	+63.15%	+66.42%	54.15B
INSMED INCORPORATED	+0.40%	-0.06%	+3.82%	+424.90%	23.11B
BIONTECH SE	-0.14%	+0.17%	-19.97%	-14.30%	23.22B
WUXI BIOLOGICS (CAYMAN) INC.	+1.03%	-0.76%	+40.14%	-3.59%	20.33B
GENMAB A/S	-0.37%	+0.71%	+31.36%	-29.32%	17.91B
SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.	+0.87%	-2.80%	+37.96%	+600.00%	15.76B
PHARMAESSENTIA CORPORATION	-2.54%	-12.88%	+168.62%	+289.45%	15B
EXELIXIS, INC.	+0.66%	-0.61%	+21.89%	+178.23%	13.82B
Average	+0.63%	-0.37%	+44.55%	+177.75%	26.51B
Weighted average by Cap.	+1.46%	+1.19%	+45.41%	+140.88%

TESARO Inc Share Price

Stocks

US8815691071

Biotechnology & Medical Research

Latest news : TESARO Inc

Press Releases: TESARO Inc

News in other languages: TESARO Inc

Quotes and Performance

Managers and Directors: TESARO Inc

Bio Therapeutic Drugs

Company Profile